Ecolab (ECL) faces "less potential for outsized stock gains" with prospects for risks and reward "balanced at current levels," UBS Securities said Monday in a report.
After 22% earnings per share growth annually in the past two years, adjusted EPS is expected to return to a "normal" range of 12% to 15%, the report said.
UBS downgraded Ecolab's stock to hold from buy with a 12-month price target of $276.
Following Q3 results, UBS trimmed 2025-26 EPS forecasts about 4% with margins and beats below expectations and pricing and costs benefits "now largely done," according to the report.
Institutional segment organic growth is expected to moderate from the current high single-digit percentage level, countered by improving growth in industrial and health care and life sciences, UBS said.
Ecolab shares fell 0.7% in recent trading Monday.
Price: 242.79, Change: -1.79, Percent Change: -0.73
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。